AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18854394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg twice daily)
Number of subjects: 19
Study 18854428 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin
Number of subjects: 3
Study 18854428 — intervention group
Group type: COMPARATOR
Intervention: Off treatment (no r-metHuLeptin)
Number of subjects: 3
Study 18854428 — intervention group
Group type: COMPARATOR
Intervention: Off-leptin OGTT
Number of subjects: 3
Study 18856012 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 40 ml/kg/h
Number of subjects: 1500
Study 18856012 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose continuous veno-venous hemodiafiltration (CVVHDF) at an effluent rate of 25 ml/kg/h
Number of subjects: 1500
Study 18856162 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab therapy
Number of subjects: 4
Study 18922099 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (22.5 mg/m2 twice daily for 2 days)
Number of subjects: 22
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of statins and beta-blockers at discharge
Number of subjects: 4402
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: C-index of the model
Number of subjects: 4402
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Point scoring system based on 8 identified factors
Number of subjects: 4402
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: 60- to 90-day postdischarge mortality rate
Number of subjects: 4402
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization rate
Number of subjects: 4402
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors predicting early postdischarge mortality
Number of subjects: 4402
Study 18926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endpoint of death or rehospitalization
Number of subjects: 4402
Study 18928574 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific acupoints of Shaoyang meridians (120 patients)
Number of subjects: 480
Study 18928574 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific acupoints of Shaoyang meridians (120 patients)
Number of subjects: 480
Study 18928574 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoints of other meridians (120 patients)
Number of subjects: 480
Study 18928574 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoints control group (120 patients)
Number of subjects: 480
Study 18928574 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 480
Study 18931344 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070) administered at doses ranging from 3.5 to 14 mg/m² as a 1-hour infusion and from 20 to 40 mg/m² as a 3-hour infusion every 3 weeks.
Number of subjects: 26
Study 18931344 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070) administered at maximum tolerated dose (MTD) of 28 mg/m² over 3 hours every 3 weeks.
Number of subjects: 26
Study 18931344 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070) administered to 26 patients.
Number of subjects: 26
Study 18936319 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-position group (both arms raised above shoulder)
Number of subjects: 177
Study 18936319 — intervention group
Group type: COMPARATOR
Intervention: One-arm group (one arm raised, one arm down)
Number of subjects: 177
Study 18936319 — intervention group
Group type: COMPARATOR
Intervention: Two-arm group (both arms down)
Number of subjects: 177
Study 18941347 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies using hormone agonists for treating uremic toxicity
Number of subjects: 0
Study 18941347 — intervention group
Group type: COMPARATOR
Intervention: Uremic toxins (rho-Cresol sulfate and indoxyl sulfate)
Number of subjects: 0
Study 18941347 — intervention group
Group type: COMPARATOR
Intervention: Impaired immunity in ESRD
Number of subjects: 0
Study 18941347 — intervention group
Group type: EXPERIMENTAL
Intervention: Disordered feeding circuits in ESRD
Number of subjects: 0
Study 18941347 — intervention group
Group type: COMPARATOR
Intervention: Mortality in ESRD
Number of subjects: 0
Study 18942885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent, CD4-guided antiretroviral treatment (ART) - Drug Conservation (DC)
Number of subjects: 499
Study 18942885 — intervention group
Group type: COMPARATOR
Intervention: Continuous ART - Viral Suppression (VS)
Number of subjects: 499
Study 18945255 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg/day) for 48 weeks
Number of subjects: 28
Study 18945347 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen (FiO(2) = 0.80)
Number of subjects: 1400
Study 18945347 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen (FiO(2) = 0.30)
Number of subjects: 1400
Study 18948732 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct ELISA
Number of subjects: 0
Study 18948732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single epitope-based inhibition ELISA
Number of subjects: 0
Study 18948732 — intervention group
Group type: COMPARATOR
Intervention: Pseudovirion-based neutralization assay (PBNA)
Number of subjects: 0
Study 18948801 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume surgeons (more than 10 cases)
Number of subjects: 871
Study 18948801 — intervention group
Group type: COMPARATOR
Intervention: Medium volume surgeons (6-10 cases)
Number of subjects: 871
Study 18948801 — intervention group
Group type: COMPARATOR
Intervention: Low volume surgeons (5 or fewer cases)
Number of subjects: 871
Study 18948801 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgeon volumes
Number of subjects: 871
Study 18950491 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Venae Sectio for TIAP insertion
Number of subjects: 100
Study 18950491 — intervention group
Group type: COMPARATOR
Intervention: Punction of V. Subclavia for TIAP insertion
Number of subjects: 100
Study 18950508 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dairy (> 3 servings/d)
Number of subjects: 338
Study 18950508 — intervention group
Group type: COMPARATOR
Intervention: Low dairy (< 1 dairy serving/d)
Number of subjects: 338
Study 18952682 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 179
Study 18952682 — intervention group
Group type: COMPARATOR
Intervention: Flat inserts
Number of subjects: 179
Study 18952682 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 179
Study 18952682 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy plus foot orthoses
Number of subjects: 179
Study 18952682 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Foot orthoses, Flat inserts, Physiotherapy, Physiotherapy plus foot orthoses)
Number of subjects: 179
Study 18952896 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate-linked radioimaging agent
Number of subjects: 0
Study 18952896 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate-linked dyes
Number of subjects: 0
Study 18952896 — intervention group
Group type: COMPARATOR
Intervention: Inflammatory stimuli (saline, thioglycolate, zymosan, heat-killed or live bacteria)
Number of subjects: 0
Study 18952896 — intervention group
Group type: EXPERIMENTAL
Intervention: FR(+) macrophages
Number of subjects: 0
Study 18954442 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242
Study 18954442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242
Study 18954442 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study 18954843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 43
Study 18955445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) with temozolomide (TMZ) (75 mg/m² daily) and radiotherapy (RT) (60 Gy)
Number of subjects: 97
Study 18955445 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg daily) with temozolomide (TMZ) (200 mg/m² daily for 5 days every 28 days)
Number of subjects: 97
Study 18955445 — intervention group
Group type: COMPARATOR
Intervention: RT/TMZ (European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981/22981)
Number of subjects: 97
Study 18955445 — intervention group
Group type: COMPARATOR
Intervention: Nitrosourea-based chemotherapy (historical controls)
Number of subjects: 97
Study 18957506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 microg twice daily for 15 d
Number of subjects: 39
Study 18971421 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45 monoclonal antibodies (mAbs)
Number of subjects: 8
Study 18971421 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous EBV-specific cytotoxic T cells (CTL)
Number of subjects: 8
Study 18971421 — intervention group
Group type: EXPERIMENTAL
Intervention: CD45 monoclonal antibodies (mAbs) followed by EBV-specific CTL infusion
Number of subjects: 8
Study 18974373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (0.1 to 3.0 mg/kg single infusion)
Number of subjects: 29
Study 18974373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3.0 mg/kg single infusion)
Number of subjects: 29
Study 18976472 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS(R) hydromorphone
Number of subjects: 200
Study 18976472 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release morphine
Number of subjects: 200
Study 18976472 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release hydromorphone
Number of subjects: 200
Study 18976472 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release hydromorphone
Number of subjects: 200
Study 18976472 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release morphine
Number of subjects: 200
Study 18976849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) doses greater than 0.4 mg/kg/d
Number of subjects: 7
Study 18976849 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg/d) alone
Number of subjects: 7
Study 18976849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 7
Study 18977647 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB assay at T0 (initial treatment)
Number of subjects: 62
Study 18977647 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB assay at TE (end of treatment)
Number of subjects: 62
Study 18977647 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB assay at TE+6 (6 months after treatment)
Number of subjects: 62
Study 18977647 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of SFUs between T0 and TE
Number of subjects: 62
Study 18977647 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome of patients with increased SFUs between T0 and TE
Number of subjects: 62
Study 18978345 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular topotecan (0.5 mg starting dose, escalated to 2 mg max dose)
Number of subjects: 5
Study 18978345 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular topotecan
Number of subjects: 5
Study 18980675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas plus ILM peeling
Number of subjects: 0
Study 18981291 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (AMG531)
Number of subjects: 142
Study 18981929 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)/endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
Number of subjects: 132
Study 18981929 — intervention group
Group type: COMPARATOR
Intervention: CT scan
Number of subjects: 132
Study 18981929 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 132
Study 18981929 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 132
Study 18983669 — intervention group
Group type: EXPERIMENTAL
Intervention: New short uncemented, proximally fixed anatomic femoral implant
Number of subjects: 200
Study 18983670 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention protocol (IP) group
Number of subjects: 78
Study 18983670 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention protocol (DP) group (usual care for 6 months)
Number of subjects: 78
Study 18986546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispatch-assisted CPR instructions
Number of subjects: 0
Study 18986546 — intervention group
Group type: COMPARATOR
Intervention: Before group (no dispatch-assisted CPR instructions)
Number of subjects: 0
Study 18986546 — intervention group
Group type: EXPERIMENTAL
Intervention: After group (with dispatch-assisted CPR instructions)
Number of subjects: 0
Study 18986547 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on CPR training and performance
Number of subjects: 0
Study 18986547 — intervention group
Group type: EXPERIMENTAL
Intervention: Final survey administered to the study population
Number of subjects: 0
Study 18987294 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) INR testing using CoaguChek S device
Number of subjects: 37
Study 18987294 — intervention group
Group type: EXPERIMENTAL
Intervention: POC INR testing in anemic patients
Number of subjects: 37
Study 18987294 — intervention group
Group type: EXPERIMENTAL
Intervention: POC INR testing in nonanemic patients
Number of subjects: 37
Study 18987294 — intervention group
Group type: EXPERIMENTAL
Intervention: POC INR testing from arteriovenous grafts
Number of subjects: 37
Study 18987294 — intervention group
Group type: EXPERIMENTAL
Intervention: POC INR testing from dialysis catheters
Number of subjects: 37
Study 18991508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental plaque biofilms
Number of subjects: 100
Study 18991508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas strains
Number of subjects: 100
Study 18991508 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory pathogens isolated from the lung
Number of subjects: 100
Study 18992649 — intervention group
Group type: EXPERIMENTAL
Intervention: MTWA non-negative (positive or indeterminate)
Number of subjects: 575
Study 18992649 — intervention group
Group type: COMPARATOR
Intervention: MTWA negative
Number of subjects: 575
Study 18992649 — intervention group
Group type: EXPERIMENTAL
Intervention: MTWA non-negative
Number of subjects: 575
Study 18992650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable everolimus-eluting coronary stent (BVS)
Number of subjects: 16
Study 18992650 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified plaques
Number of subjects: 16
Study 18992650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronecrotic plaques
Number of subjects: 16
Study 18992650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrocellular plaque
Number of subjects: 16
Study 18997171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 UCB units
Number of subjects: 265
Study 18997171 — intervention group
Group type: COMPARATOR
Intervention: 1 UCB unit
Number of subjects: 265
Study 18997171 — intervention group
Group type: EXPERIMENTAL
Intervention: double UCBT
Number of subjects: 265
Study 18997171 — intervention group
Group type: COMPARATOR
Intervention: single UCBT
Number of subjects: 265
Study 18997171 — intervention group
Group type: EXPERIMENTAL
Intervention: grade II-IV acute GVHD
Number of subjects: 265
Study 18997681 — intervention group
Group type: EXPERIMENTAL
Intervention: Food frequency questionnaire (FFQ) for dietary intake assessment
Number of subjects: 93
Study 18997681 — intervention group
Group type: COMPARATOR
Intervention: Plasma carotenoid concentrations
Number of subjects: 93
Study 19001517 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSA) only (group A; n = 34)
Number of subjects: 100
Study 19001517 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (group C; n = 30)
Number of subjects: 100
Study 19001517 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by SSA (group D; n = 16)
Number of subjects: 100
Study 19001517 — intervention group
Group type: COMPARATOR
Intervention: SSA followed by surgery (group B; n = 20)
Number of subjects: 100
Study 19001517 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SSA treatment
Number of subjects: 100
Study 19001517 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study 19001517 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients receiving SSA
Number of subjects: 100
Study 19001517 — intervention group
Group type: COMPARATOR
Intervention: Patients not receiving SSA
Number of subjects: 100
Study 19005394 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 40
Study 19005394 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide therapy
Number of subjects: 40
Study 19005394 — intervention group
Group type: COMPARATOR
Intervention: Single islet infusion or islet after kidney transplant
Number of subjects: 40
Study 19005394 — intervention group
Group type: COMPARATOR
Intervention: Longer diabetes duration, higher insulin dosage, and occurrence of adverse events
Number of subjects: 40
Study 19005970 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin C (358.0 mg/day)
Number of subjects: 133614
Study 19005970 — intervention group
Group type: COMPARATOR
Intervention: Dietary antioxidants, carotenoids, and vitamin A
Number of subjects: 133614
Study 19005970 — intervention group
Group type: COMPARATOR
Intervention: Dietary intake at baseline
Number of subjects: 133614
Study 19005970 — intervention group
Group type: COMPARATOR
Intervention: Overall dietary intake of antioxidants
Number of subjects: 133614
Study 19008157 — intervention group
Group type: EXPERIMENTAL
Intervention: Older HIV(+) subjects
Number of subjects: 0
Study 19012935 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin A3 quantification in urine
Number of subjects: 591
Study 19012935 — intervention group
Group type: COMPARATOR
Intervention: Percent free prostate specific antigen
Number of subjects: 591
Study 19012935 — intervention group
Group type: EXPERIMENTAL
Intervention: Annexin A3
Number of subjects: 591
Study 19014833 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg/d (with option to increase to 10 mg at weeks 4 and 8)
Number of subjects: 441
Study 19015393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² per day for 5 days for 6 cycles) and Rituximab (375 mg/m² per week for 8 infusions)
Number of subjects: 43
Study 19015393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and Rituximab
Number of subjects: 43
Study 19018755 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab tiuxetan (11.1 MBq/kg)
Number of subjects: 40
Study 19018755 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab tiuxetan (14.8 MBq/kg)
Number of subjects: 40
Study 19018755 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab tiuxetan
Number of subjects: 40
Study 19019244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (50 mg/day)
Number of subjects: 21657
Study 19020433 — intervention group
Group type: EXPERIMENTAL
Intervention: II genotype
Number of subjects: 180
Study 19020433 — intervention group
Group type: EXPERIMENTAL
Intervention: ID genotype
Number of subjects: 180
Study 19020433 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype distribution
Number of subjects: 180
Study 19020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (anti-EGFR antibody)
Number of subjects: 0
Study 19020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (single agent)
Number of subjects: 0
Study 19020749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + CDDP (optimal doses)
Number of subjects: 0
Study 19020749 — intervention group
Group type: COMPARATOR
Intervention: CDDP (cisplatin)
Number of subjects: 0
Study 19023036 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 19025583 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle counselling in addition to individual lifestyle counselling
Number of subjects: 2356
Study 19025583 — intervention group
Group type: COMPARATOR
Intervention: Individual lifestyle counselling
Number of subjects: 2356
Study 19025602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup feeding (n = 30)
Number of subjects: 60
Study 19025602 — intervention group
Group type: COMPARATOR
Intervention: Bottle feeding (n = 30)
Number of subjects: 60
Study 19026265 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 153
Study 19029442 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2449
Number of subjects: 0
Study 19032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF), Abacavir (ABC), Lamivudine (3TC)
Number of subjects: 0
Study 19032103 — intervention group
Group type: EXPERIMENTAL
Intervention: K65R and/or M184V mutations with wild-type virus
Number of subjects: 0
Study 19032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level nucleoside reverse-transcriptase inhibitor-resistant HIV
Number of subjects: 0
Study 19032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixtures versus mutants in a clinical-isolate database
Number of subjects: 0
Study 19032759 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 871
Study 19032759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitive C-reactive protein (hsCRP)
Number of subjects: 871
Study 19033011 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab (EA group: abciximab started before admission to cathlab, at least 30 minutes before balloon)
Number of subjects: 1650
Study 19033011 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab (LA group: periprocedural administration of abciximab in the cathlab)
Number of subjects: 1650
Study 19033011 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab (EA group)
Number of subjects: 1650
Study 19033011 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab (LA group)
Number of subjects: 1650
Study 19037628 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 8
Study 19037628 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 8
Study 19037628 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 19038036 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-dose regimen of artemether-lumefantrine (AL) tablets
Number of subjects: 103